Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Janku F, Hess KR, Yap TA.

JAMA Oncol. 2018 Nov 8. doi: 10.1001/jamaoncol.2018.5064. [Epub ahead of print] No abstract available.

PMID:
30419079
2.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2018 Oct 25. doi: 10.1002/cncr.31811. [Epub ahead of print]

PMID:
30359477
3.

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2018 Sep 4. doi: 10.1158/1078-0432.CCR-18-1446. [Epub ahead of print]

PMID:
30181387
4.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

PMID:
30139837
5.

Sex as a predictor of response to cancer immunotherapy.

McQuade JL, Daniel CR, Hess KR, Davies MA.

Lancet Oncol. 2018 Aug;19(8):e376. doi: 10.1016/S1470-2045(18)30483-2. No abstract available.

PMID:
30102226
6.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Jul 10. pii: S1526-8209(18)30009-0. doi: 10.1016/j.clbc.2018.07.008. [Epub ahead of print]

PMID:
30077429
7.

Imaging of Intracystic Papillary Carcinoma.

Speer ME, Adrada BE, Arribas EM, Hess KR, Middleton LP, Whitman GJ.

Curr Probl Diagn Radiol. 2018 May 22. pii: S0363-0188(18)30081-1. doi: 10.1067/j.cpradiol.2018.05.001. [Epub ahead of print]

PMID:
30072190
8.

Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review.

Gupta V, Coburn N, Kidane B, Hess KR, Compton C, Ringash J, Darling G, Mahar AL.

J Thorac Cardiovasc Surg. 2018 Aug;156(2):847-856. doi: 10.1016/j.jtcvs.2018.03.146. Epub 2018 Apr 12.

PMID:
30011772
9.

Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord.

Vedantam A, Bruera E, Hess KR, Dougherty PM, Viswanathan A.

Neurosurgery. 2018 Jul 13. doi: 10.1093/neuros/nyy330. [Epub ahead of print]

PMID:
30011044
10.

High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up.

Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM.

Br J Radiol. 2018 Oct;91(1090):20180300. doi: 10.1259/bjr.20180300. Epub 2018 Jul 5.

PMID:
29947265
11.

An effort expenditure perspective on cancer-related fatigue.

Lacourt TE, Vichaya EG, Escalante C, Manzullo EF, Gunn B, Hess KR, Heijnen CJ, Dantzer R.

Psychoneuroendocrinology. 2018 Oct;96:109-117. doi: 10.1016/j.psyneuen.2018.06.009. Epub 2018 Jun 9.

PMID:
29929087
12.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
13.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

PMID:
29668571
14.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

PMID:
29579338
15.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

16.

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

Levin VA, Ictech SE, Hess KR.

CNS Oncol. 2018 Apr;7(2):CNS16. doi: 10.2217/cns-2017-0031. Epub 2018 Jan 30.

17.

Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.

Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L.

JAMA Oncol. 2018 Apr 12;4(4):e175092. doi: 10.1001/jamaoncol.2017.5092. Epub 2018 Apr 12.

PMID:
29372234
18.

Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.

Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ.

J Radiosurg SBRT. 2017;5(1):25-34.

19.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

20.

Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy.

Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G.

J Neurooncol. 2018 Mar;137(1):57-65. doi: 10.1007/s11060-017-2694-3. Epub 2017 Dec 4.

PMID:
29204838
21.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

22.

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.

Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.

PMID:
29161986
23.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

PMID:
29159766
24.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

25.

Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.

Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx094.

26.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

27.

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27.

PMID:
29075985
28.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

29.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J.

Radiother Oncol. 2017 Oct;125(1):80-88. doi: 10.1016/j.radonc.2017.08.009. Epub 2017 Sep 12.

PMID:
28916225
30.

A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.

Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E.

J Natl Compr Canc Netw. 2017 Sep;15(9):1111-1120. doi: 10.6004/jnccn.2017.0149.

PMID:
28874596
31.

Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.

Mahar AL, Compton C, Halabi S, Hess KR, Weiser MR, Groome PA.

J Surg Oncol. 2017 Dec;116(8):969-982. doi: 10.1002/jso.24774. Epub 2017 Aug 2. Review.

PMID:
28767139
32.

TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation.

Hossain MB, Shifat R, Li J, Luo X, Hess KR, Rivera-Molina Y, Puerta Martinez F, Jiang H, Lang FF, Hung MC, Fueyo J, Gomez-Manzano C.

Mol Cell Biol. 2017 Oct 13;37(21). pii: e00142-17. doi: 10.1128/MCB.00142-17. Print 2017 Nov 1.

33.

Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer.

Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR.

Clin Exp Metastasis. 2017 Jun;34(5):315-322. doi: 10.1007/s10585-017-9850-1. Epub 2017 Jul 25.

PMID:
28744603
34.

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM.

Cancer Chemother Pharmacol. 2017 Sep;80(3):583-589. doi: 10.1007/s00280-017-3391-9. Epub 2017 Jul 20.

PMID:
28730293
35.

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]

PMID:
28729355
36.

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.

Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G.

Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433. Lancet Oncol. 2017 Sep;18(9):e510.

37.

Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.

Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF.

Neuro Oncol. 2017 May 1;19(5):660-668. doi: 10.1093/neuonc/now239.

38.

Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma.

Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, Grubbs EG, Lee JE, Busaidy NL, Perrier ND.

J Am Coll Surg. 2017 Mar 15. pii: S1072-7515(17)30179-5. doi: 10.1016/j.jamcollsurg.2017.01.060. [Epub ahead of print]

PMID:
28427885
39.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

40.

Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy.

Le-Petross HT, Hess KR, Knudtson JD, Lane DL, Moseley TW, Geiser WR, Whitman GJ.

Curr Probl Diagn Radiol. 2017 Nov - Dec;46(6):410-414. doi: 10.1067/j.cpradiol.2017.02.001. Epub 2017 Feb 16.

PMID:
28390794
41.

Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.

Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285.

42.

Postoperative MRI Evaluation of a Radiofrequency Cordotomy Lesion for Intractable Cancer Pain.

Vedantam A, Hou P, Chi TL, Hess KR, Dougherty PM, Bruera E, Viswanathan A.

AJNR Am J Neuroradiol. 2017 Apr;38(4):835-839. doi: 10.3174/ajnr.A5100. Epub 2017 Feb 16.

43.

Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up.

Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT.

AJR Am J Roentgenol. 2017 Apr;208(4):916-922. doi: 10.2214/AJR.16.16576. Epub 2017 Jan 31.

PMID:
28140609
44.

Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain.

Vedantam A, Hou P, Chi TL, Dougherty PM, Hess KR, Viswanathan A.

Stereotact Funct Neurosurg. 2017;95(1):34-39. doi: 10.1159/000453279. Epub 2017 Jan 14.

45.
46.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
47.

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.

Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM.

Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380.

48.

Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual.

Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1407-1413. doi: 10.1158/1078-0432.CCR-16-1936. Epub 2016 Nov 16.

49.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

50.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

Supplemental Content

Support Center